Hongyuan Pharmaceutical (301246.SZ): The '6,000-ton-per-year high-purity crystalline lithium hexafluorophosphate capacity expansion project' is about to enter the trial production phase.

Gelonghui, June 4 — Hongyuan Pharmaceutical (301246.SZ) stated on an investor interaction platform that its '6,000-ton-per-year high-purity crystalline lithium hexafluorophosphate expansion and renovation project' is about to enter the trial production phase. For specific progress and the expected completion and commissioning timeline, please refer to the company's official disclosures.

Gelonghui FinanceJun 4 09:11

Hongyuan Pharmaceutical (301246.SZ): Paid tax of RMB 18.5673 million

Gelonghui, June 1 — Hongyuan Pharmaceutical (301246.SZ) announced that, following an internal review, the company is required to pay an additional RMB 18.5673 million in enterprise income tax for the 2025 fiscal year. As of the date of this announcement, the company has fully paid the aforementioned tax amount as required. Since the supplementary payment falls within the enterprise income tax reconciliation period, no late payment penalties apply.

Gelonghui FinanceJun 1 15:57

Hongyuan Pharmaceutical (301246): Active Pharmaceutical Ingredients as a Shield to Build Moats, Lithium Hexafluorophosphate as a Spear to Drive Growth

"Pharmaceuticals + Lithium Batteries" dual-engine drive. Hongyuan Pharmaceutical is a high-tech enterprise primarily engaged in pharmaceuticals and lithium battery materials. The company has not only established a relatively complete pharmaceutical industry chain but is also among the earliest domestic enterprises to achieve industrial-scale mass production of lithium hexafluorophosphate.

Shenwan Hongyuan ResearchMay 28 07:22

Hongyuan Pharmaceutical's non-GAAP net profit attributable to shareholders reached 90.3 million yuan in 2025, representing a year-on-year increase of 871.30%. Lithium hexafluorophosphate has become the primary growth driver.

In 2025, the company's revenue reached RMB 1.939 billion (+9.53%), with a net profit attributable to shareholders of RMB 119 million (+131.33%) and a non-recurring net profit of RMB 90.3 million (+871.30%). The net profit margin rose to 6.14%. The lithium hexafluorophosphate business became the core growth driver, contributing 34.77% of revenue while gross margin increased significantly by 22.99 percentage points. However, operating cash flow was negative at RMB -185 million, reflecting a temporary mismatch between profits and collections.

lanjinger.comApr 29 15:43

Hongyuan Pharmaceutical: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Hongyuan Pharmaceutical: 2025 Annual Report

SZSIApr 29 00:00 · Announcements